Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed, locally advanced or
             metastatic solid tumors who are not candidates for standard therapy or in whom
             regorafenib or cetuximab is considered a standard treatment. Patients with metastatic
             colorectal cancer (mCRC) must have a record of K-ras gene mutational analysis
             available and no K-ras mutation is present.

          -  Male or female patients ≥ 18 years of age

          -  Women of childbearing potential must have a blood or urine pregnancy test performed a
             maximum of 7 days before start of study treatment, and a negative result must be
             documented before start of study treatment

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements conducted within 7 days of starting the study treatment:

               -  Platelet count ≥ 100,000/cubic millimeters (mm3), hemoglobin (Hb) ≥ 8.5 g/dl,
                  leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,000/mm3

               -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). Mildly elevated total
                  bilirubin (< 6 mg/dL) is allowed if Gilbert's syndrome is documented.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN
                  (≤ 5 x ULN for subjects with liver involvement of their cancer)

               -  Alkaline phosphatase limit ≤ 2.5 x ULN (≤ 5 x ULN for subjects whose cancer
                  involves their liver).

               -  Amylase and lipase ≤ 1.5 x ULN

               -  Serum creatinine ≤ 1.5 times ULN and creatinine clearance (CLcr) ≥ 30 mL/min
                  according to the Cockroft-Gault formula

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          -  Prior treatment with Regorafenib

          -  Prior discontinuation of cetuximab treatment due to toxicity or intolerance of
             cetuximab

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication

          -  Non-healing wound, ulcer, or bone fracture

          -  Systemic anticancer therapy within 28 days

          -  Patients unable to swallow and retain oral medications